Third Quarter 2026 Financial Results & Corporate Update November 3, 2026 Exhibit 99.1
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech’s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech’s partners; the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine and, if approved, BioNTech’s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech’s expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; BioNTech’s expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech’s expectations with respect to intellectual property; the impact of BioNTech’s collaboration and licensing agreements, including BioNTech’s partnership with BMS; BioNTech's expectations with respect to developments in law, public policy, and international trade; BioNTech’s estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech’s expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward- looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this presentation, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech’s pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech’s other product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech’s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; expected changes to BioNTech’s leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. Furthermore, certain statements contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and BioNTech’s own internal estimates and research. While BioNTech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, any market data included in this presentation involves assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. While BioNTech believes its own internal research is reliable, such research has not been verified by any independent source. In addition, BioNTech is the owner of various trademarks, trade names and service marks that may appear in this presentation. Certain other trademarks, trade names and service marks appearing in this presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this presentation may be referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. 2 An abbreviation directory of defined terms can be found at the end of the presentation. To be updated by Legal This Slide Presentation Includes Forward-Looking Statements
1 Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 2 Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 3 Financial Performance Ramón Zapata, Chief Financial Officer 3
Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 1 4
ONCOLOGY FOCUS IN 2026 PROGRESS IN Q3 Late-Stage Acceleration Key late-stage data readouts expected for first wave of oncology assets Gotistobart clinical benefit validated in OS data presented at WCLC Combination Therapy Momentum Pumitamig1 + ADC combination to advance into registrational path Pumitamig + TROP2 ADC3 to be evaluated in global Phase 3 trial Modalities to Disease Areas Transition to a focused disease area specific approach Strong Pumitamig + B7H3 ADC2 data presented at WCLC and ESMO 1 2 3 5 Partnered with 1. Bristol Myers Squibb; 2. DualityBio; 3. Phase 3 collaboration with Gilead.
Building a Multi-Product Company Across Tumor Focus Areas by 2030+ Targeting 17+ Late-Stage and Pivotal Trial Readouts Informing Multiple Launch Opportunities 6 Tumor Type Incidence1 Assets Late-Stage/Pivotal Trials Expected Data Readouts2 2026 2027 2028 2029 2030+ Lung 1L NSCLC 400K Pumitamig3 ROSETTA Lung-02 Stage III unresectable NSCLC 65K Pumitamig3 ROSETTA Lung-201 1L NSCLC – PD-L1 ≥ 50% 60K Pumitamig3 ROSETTA Lung-202 2L+ sqNSCLC1 55K Gotistobart4 PRESERVE-003 1L ES-SCLC 80K Pumitamig3 ROSETTA Lung-01 Breast 1L TNBC – all comers 20K Pumitamig3 Phase 3 in China 1L TNBC – PD-L1- 15K Pumitamig3 ROSETTA Breast-017,9 2L+ HR+ BC1 – HER2-low 55K Trastuzumab pamirtecan5 DYNASTY Breast-02 Genitourinary 1L RCC 40K Pumitamig3 ROSETTA RCC-2088 1L CRPC 110K Elfetabart drozuntecan5 BNT324-03 Gastrointestinal 1L MSS-CRC 230K Pumitamig3 ROSETTA CRC-203 1L Gastric – HER2-neg, PD-L1+ 40K Pumitamig3 ROSETTA Gastric-204 1L HCC 25K Pumitamig3 ROSETTA HCC-2068 Adj. PDAC 30K Autogene cevumeran6 IMCODE003 Gynecologic 2L+ Endometrial1 – HER2-expressing 10K Trastuzumab pamirtecan5 Single-arm Phase 2 Trastuzumab pamirtecan5 Fern-EC-01 Additional Tumors 1L HNSCC – PD-L1 CPS ≥ 1, HPV16+ 50K BNT113 AHEAD-MERIT 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb. 2026; incidence information for informational purposes only and not intended to indicate the potential market size or reach of BioNTech’s and its collaborators’ product candidates, if approved. 2. Expected data readouts may be from interim or final analyses, are event-driven and in some cases may not translate into commercial launches; Partnered with: 3. Bristol Myers Squibb; 4. OncoC4; 5. DualityBio; 6. Genentech, a member of the Roche group; 7. Phase 3 collaboration with Gilead; 8. Phase 1/2 trials; anticipated pivotal trials evaluating pumitamig in these tumor types are expected to readout after 2030. 9. Expected primary completion date to be updated after clinicaltrials.gov update.
Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 3 7
Tumor-type Focused Strategy to Address Significant Oncology Unmet Medical Needs 8 GastrointestinalBreastLung Genitourinary Gynecologic Additional Tumors Data presented at WCLC and ESMO validate clinical benefit of BioNTech’s product candidates across key tumor types
Elfetabart Drozuntecan3 Unique Opportunity to Build a Diversified Lung Cancer Franchise 9 Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. DualityBio. Gotistobart2Pumitamig1 Bispecific antibody targeting PD-L1 and VEGF-A with next- gen IO backbone potential TME-selective regulatory T cell-depleting antibody targeting CTLA-4 Novel pan-tumor ADC targeting B7H3 with favorable safety profile
NSCLC SCLC Resectable Stage III Unresectable 1L Metastatic 2L+ Metastatic 1L Metastatic 2L+ Metastatic Incidence1 220K 65K 400K 230K 80K 35K Broadening BioNTech’s Lung Cancer Coverage to Maximize Pipeline Potential 10 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information for informational purposes only and not intended to indicate the potential market size or reach of BioNTech’s and its collaborators’ product candidates, if approved; Partnered with: 2. Bristol Myers Squibb; 3. OncoC4; 4. DualityBio; 5. MediLink (BNT326/YL202); 6. Being conducted in China. Next Generation IO Targeted Therapy mRNA Immunotherapy Registrational Trials Phase 1/2 PoC Trials Gotistobart3 PRESERVE-003 (sq) FixVac + Gotistobart3/ADCs LuCa-MERIT-1 Pumitamig2 + chemo IIT6 Pumitamig2 + chemo ROSETTA LUNG-02 ADC monos Elfetabart drozuntecan4, Sacituzumab drozuntecan4, Beruzatatug pelitecan5 Pumitamig2 + ADCs Elfetabart drozuntecan4, Sacituzumab drozuntecan4, Beruzatatug pelitecan5 Pumitamig2 ROSETTA LUNG-201 Pumitamig2 + FixVac LuCa-MERIT-1 Pumitamig2 ROSETTA LUNG-202 Pumitamig2 + chemo ROSETTA LUNG-01 Pumitamig2 + ADC (Elfetabart drozuntecan4) Pumitamig2 + TCE ADC mono Elfetabart drozuntecan4
Gotistobart Phase 3 Data Show Nearly Doubled Median Overall Survival vs SoC 11 Gotistobart (n=45) Docetaxel (n=42) Median OS, mos. 10.0 HR 0.56 Partnered with: 1. OncoC4, 2. Data presented at WCLC 2026. Median OS was 18.5 months with gotistobart1 vs 10.0 months with docetaxel2 Gotistobart continues to show potential as chemotherapy-free treatment option in a hard-to-treat lung cancer setting Gotistobart reduced the risk of death by 44% vs. chemotherapy 25.4 month follow-up data from non-pivotal part of Phase 3 presented at WCLC 2026 Observed overall safety profile aligns with its previously established safety findings Pivotal Phase 3 in sqNSCLC ongoing with gotistobart monotherapy as chemo-free 2L+ treatment option First interim analysis of pivotal Phase 3 expected in 2026 Development Status Clinical Evidence
NSCLC SCLC Resectable Stage III Unresectable 1L Metastatic 2L+ Metastatic 1L Metastatic 2L+ Metastatic Incidence1 220K 65K 400K 230K 80K 35K Broadening BioNTech’s Lung Cancer Coverage to Maximize Pipeline Potential 12 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information for informational purposes only and not intended to indicate the potential market size or reach of BioNTech’s and its collaborators’ product candidates, if approved; Partnered with: 2. Bristol Myers Squibb; 3. OncoC4; 4. DualityBio; 5. MediLink (BNT326/YL202); 6. Being conducted in China. Next Generation IO Targeted Therapy mRNA Immunotherapy Registrational Trials Phase 1/2 PoC Trials Gotistobart3 PRESERVE-003 (sq) FixVac + Gotistobart3/ADCs LuCa-MERIT-1 Pumitamig2 + chemo IIT6 Pumitamig2 + chemo ROSETTA LUNG-02 ADC monos Elfetabart drozuntecan4, Sacituzumab drozuntecan4, Beruzatatug pelitecan5 Pumitamig2 + ADCs Elfetabart drozuntecan4, Sacituzumab drozuntecan4, Beruzatatug pelitecan5 Pumitamig2 ROSETTA LUNG-201 Pumitamig2 + FixVac LuCa-MERIT-1 Pumitamig2 ROSETTA LUNG-202 Pumitamig2 + chemo ROSETTA LUNG-01 Pumitamig2 + ADC (Elfetabart drozuntecan4) Pumitamig2 + TCE ADC mono Elfetabart drozuntecan4
Pumitamig1 plus ADC elfe-D2 elicits 70.4% ORR in SCLC3 –100 –80 –60 –40 –20 0 20 40 60 Pe rc en ta ge c ha ng e fr om b as el in e (% ) Pumitamig + Elfetabart Drozuntecan Demonstrates Early Antitumor Activity Across SCLC Treatment Lines 13 ORR Overall (n=71) 70.4% 1L (n=13) 92.3% 2L (n=21) 76.2% 3L+ (n=21) 52.4% ORR Prior IO (n=48) 60.4% ORR Prior DLL3-TCE (n=8) 87.5% Elfe-D 6 mg/kg + pumitamig 30 mg/kg Elfe-D 4.5 mg/kg + pumitamig 30 mg/kg Elfe-D 6 mg/kg + pumitamig 20 mg/kg Elfe-D 4.5 mg/kg + pumitamig 20 mg/kg Clinical development strategy to address today’s unmet need and tomorrow’s evolving SCLC standard of care Partnered with 1. Bristol Myers Squibb; 2. DualityBio, 3. Data presented at WCLC 2026. First global efficacy data for a PD-(L)1xVEGF bsAb + ADC in lung cancer Encouraging early efficacy in SCLC across treatment lines and dose levels High response rates in patients previously treated with emerging SoC Manageable safety profile and limited overlap between pumitamig- and elfe-D- associated toxicities Clinical Evidence
Pumitamig + ADC Combination Development Enters Pivotal Phase 14 1. Phase 1/2 Data presented at ESMO BREAST 2026. Partnered with: 2. Bristol Myers Squibb; 3. DualityBio; 4. Phase 3 collaboration with Gilead. ROSETTA Breast-01: An ongoing Phase 3 trial updated to reflect the evolving 1L TNBC standard of care in collaboration with Gilead4 1:1 BioNTech’s first global Phase 3 combination trial evaluating pumitamig and an antibody-drug conjugate Compelling Phase 1/2 proof-of-concept data1 for pumitamig2 + TROP23 ADC support BioNTech’s clinical strategy in 1L TNBC 0 25 –25 –50 –75 –100B es t p er ce nt ag e ch an ge fr om b as el in e (% ) Median follow-up: 7.7 months Stable disease Partial response Pumitamig + BNT325 (n=30) Confirmed ORR, % 76.7% DCR, % 96.7% DoR, months NE (6.3, NE) 1L TNBC ARM A Pumitamig + sacituzumab govitecan ARM B Placebo + sacituzumab govitecan
mRNA Cancer Immunotherapy iNeST and FixVac Portfolio Development Focus 15 Partnered with: 1. Genentech, a member of the Roche Group; 2. In collaboration with Regeneron. Autogene cevumeran1 BNT113 BNT116 Adjuvant Adjuvant 1L Multiple settings CRC Phase 2 PDAC Phase 2 HPV16+ PD-L1 CPS ≥1 HNSCC Phase 2/3 NSCLC Phase 1 & 2 Monotherapy + Atezolizumab + mFOLFIRINOX + Pembrolizumab Mono & combo with IO & ADCs • Study terminated • Recruitment completed • Data from Phase 1 trial published: Rojas et al., Nature 2023; Sethna et al., Nature 2025, 6-year data update presented at AACR 2026 • Recruitment ongoing • Trial updated to Phase 2/3 • Recruitment completed in Phase 2 in 1L NSCLC2 • Data presented at SITC 2023, AACR 2024, SITC 2024 and AACR 2026 • Data in frail patients presented at AACR 2025 • Data in patients after CRT presented at WCLC 2025 • Data for neoadjuvant BNT116 + cemi + chemo presented at WCLC 2026 Primary completion date expected in 2031 Did not meet PFS at IA; Trial continues for OS Individualized Immunotherapy – iNeST1 Off-the-shelf Immunotherapy – FixVac
Multiple Milestones Achieved so Far in 2026 16 Program Trial Readout Phase Indication Status Context Late-Stage Trial Readouts Trastuzumab pamirtecan3 Single arm Phase 2 2L+ HER2-expressing endometrial cancer Achieved Phase 35 primary analysis Chemo naïve HR+ HER2-low breast cancer Achieved in Q3 Met PFS, modest improvement Gotistobart2 Phase 35 interim analysis 2L+ sqNSCLC On track Phase 2 2L+ mCRPC6 Updated Data maturity BNT113 Phase 35 interim analysis 1L HPV16+ PD-L1 CPS ≥1 HNSCC Achieved in Q3 Did not meet PFS, continues for OS Pumitamig1 Phase 35 in China interim analysis 1L TNBC6 Updated Data maturity Early-Stage Pumitamig & ADC Trial Readouts Pumitamig1 Phase 2 1L NSCLC Achieved Phase 2 1L ES-SCLC Achieved Phase 2 in China 1L HCC6 Updated Data maturity Phase 2 in China 1L MSS-CRC7 Updated Sample size increase Pumitamig1 + Trastuzumab pamirtecan3 Phase 1/2 Breast cancer Achieved in Q3 Pumitamig1 + Elfetabart drozuntecan3 Phase 2 Advanced solid tumors Achieved in Q3 Phase 1/2 NSCLC/SCLC Achieved in Q3 Pumitamig1 + Sacituzumab drozuntecan3 Phase 2 TNBC Achieved Pumitamig1 + Beruzatatug pelitecan4 Phase 1/2 NSCLC6 Updated Data maturity Elfetabart drozuntecan3 Phase 1/2 2L+ mCRPC Achieved Phase 3 Trial Initiations Pumitamig1 Phase 35 1L MSS-CRC Achieved 1L HER2- PD-L1+ gastric cancer Achieved 1L NSCLC – PD-L1 ≥ 50% Achieved Stage III unresectable NSCLC Achieved Elfetabart drozuntecan3 Phase 3 1L mCRPC Achieved BLA Submission Trastuzumab pamirtecan3 - 2L+ HER2-expressing endometrial cancer Updated Under discussion8 Some data readouts may be event-driven and subject to change based on actual event accrual rates or publication strategy. Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. DualityBio; 4. MediLink; 5. Pivotal trial. 6. The timing of this readout is no longer expected in 2026 due to data maturity. 7. The timing of this readout is no longer expected in 2026 due to an increase in the enrollment target of the trial. 8. BioNTech and DualityBio are discussing plans for BLA submission and will update the markets accordingly.
Financial Performance Ramón Zapata, Chief Financial Officer 4 17
In € millions except per share data1 Q3 2026 Q3 2025 IFRS Results Adjusted Results2 IFRS Results Adjusted Results2 Revenues 1,289 1,289 1,519 1,519 Cost of sales (103) (92) (148) (148) Research and development expenses (748) (579) (565) (479) Sales, marketing, general and administrative expenses (179) (179) (149) (149) Other operating result (134) (59) (704) (8) Operating profit / (loss) 125 381 (47) 734 Net profit / (loss) 185 441 (29) 753 Diluted earnings / (loss) per share 0.73 1.76 (0.12) 3.11 Weighted average number of shares outstanding (millions) 4 251 251 241 242 Third Quarter 2026 Financial Results Revenue from BMS partnership driving quarterly results 18 Balance Sheet as of September 30, 2026 – Cash and cash equivalents plus security investments3 €16.2 bn 1. All numbers have been rounded and may not add up to the totals. Presentation of the unaudited interim consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech’s results determined in accordance with International Financial Reporting Standards (“IFRS”), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix “Adjusted” or, as a whole, “Adjusted Results”). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech’s measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech’s Report on Form 6-K for the period ended September 30, 2026, filed on November 3, 2026, which is available at www.sec.gov. The weighted average number of shares outstanding is excluded from that reconciliation. While non-IFRS measures may offer additional insights, BioNTech’s non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Cash and cash equivalents plus security investments as of as of September 30, 2026, reached €16,163.8 million, comprising €10,200.8 million in cash and cash equivalents, €4,390.2 million in current security investments disclosed as financial assets and €1,572.8 million in non-current security investments disclosed as financial assets. 4. Only basic EPS are calculated in loss making periods. Diluted EPS are including outstanding instruments from BioNTech’s Share-Based Payment programs. The weighted average number of shares outstanding is determined as described in our Annual Report on Form 20-F as of and for the year ended December 31, 2025, as amended and is not adjusted by non-IFRS measures.
Q3 Year-to-Date 2026 Financial Results at a Glance1 Continued Focus on R&D Priority Programs 19 Revenues € 1,513 MILLION vs. €1,963 million year-to-date 2025 Adjusted R&D Expenses² € 1,583 MILLION vs. €1,514 million year-to-date 2025 IFRS R&D Expenses: €1,856 million vs. €1,600 million year-to-date 2025 Adjusted SG&A Expenses² € 527 MILLION vs. €407 million year-to-date 2025 IFRS SG&A Expenses: €527 million vs. €407 million year-to-date 2025 1. All numbers have been rounded. Presentation of the unaudited interim consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech’s results determined in accordance with International Financial Reporting Standards (“IFRS”), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix “Adjusted” or, as a whole, “Adjusted Results”). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech’s measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech’s Report on Form 6-K for the period ended September 30, 2026, filed on November 3, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech’s non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. Unless otherwise indicated, Adjusted Results are identical to IFRS Results.
Updated Full Year 2026 Financial Guidance1 1. Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions (“M&A”) transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech’s Report on Form 6-K for the period ended September 30, 2026, filed on November 3, 2026, which is available at www.sec.gov. FY 2026 non-IFRS Guidance In € millions Current Nov. 3, 2026 Prior Aug. 4, 2026 Revenues 1,700 – 1,900 1,600 – 1,900 Adjusted R&D Expense Unchanged 2,000 – 2,300 Adjusted SG&A Expense Unchanged 700 - 800
Thank you
Appendix
Reconciliation of IFRS to Adjusted Results – Q3 2026 & 2025 Financial Results In € millions except per share data1 Q3 2026 Q3 2025 IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 1,289 – 1,289 1,519 – 1,519 Cost of sales (103) 11 (92) (148) – (148) Research and development expenses (748) 170 (579) (565) 85 (479) Sales, marketing, general and administrative expenses (179) – (179) (149) – (149) Other operating result (134) 75 (59) (704) 696 (8) Operating profit / (loss) 125 256 381 (47) 781 734 Net profit / (loss)3 185 256 441 (29) 781 753 Diluted earnings / (loss) per share 0.73 1.76 (0.12) 3.11 1. All Numbers have been rounded and may not add up to the totals. Presentation of the unaudited interim consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech’s results determined in accordance with International Financial Reporting Standards (“IFRS”), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix “Adjusted” or, as a whole, “Adjusted Results”). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech’s measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech’s Report on Form 6-K for the period ended September 30, 2026, filed on November 3, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech’s non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Tax effects are not considered as part of BioNTech’s non-IFRS adjustments. 23
Reconciliation of IFRS to Adjusted Results – YTD 2026 & 2025 Financial Results In € millions except per share data1 Year-to-date 2026 Year-to-date 2025 IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 1,513 – 1,513 1,963 – 1,963 Cost of sales (272) 11 (261) (308) – (308) Research and development expenses (1,856) 273 (1,583) (1,600) 85 (1,514) Sales, marketing, general and administrative expenses (527) – (527) (407) – (407) Other operating result (359) 268 (91) (730) 719 (11) Operating loss (1,501) 552 (948) (1,082) 804 (278) Net loss3 (1,168) (616) (831) (27) Diluted loss per share (4.63) (2.44) (3.45) (0.11) 1. All Numbers have been rounded and may not add up to the totals. Presentation of the unaudited interim consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech’s results determined in accordance with International Financial Reporting Standards (“IFRS”), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix “Adjusted” or, as a whole, “Adjusted Results”). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech’s measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech’s Report on Form 6-K for the period ended September 30, 2026, filed on November 3, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech’s non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Tax effects are not considered as part of BioNTech’s non-IFRS adjustments. 24
BioNTech’s Oncology Pipeline 25 Partnered with: 1. Bristol Myers Squibb; 2. Genentech, a member of the Roche Group; 3. DualityBio; 4. OncoC4; 5. MediLink; 6. Genmab; 7. In collaboration with Regeneron; 8. Trial ongoing in China only; 9. Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to pumitamig; 10. Phase 3 collaboration with Gilead. Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 BNT116 Adv. NSCLC BNT317 Multiple solid tumors Pumitamig1 Adv. RCC Pumitamig1 + Beruzatatug pelitecan5 Multiple solid tumors Autogene cevumeran2 Adj. PDAC Pumitamig1 2L ES-SCLC8 Tenumomeran/ Raplemomeran 1L HPV16+ HNSCC Elfetabart Drozuntecan3 Met. CRPC Pumitamig1 1L adv./met.TNBC8 BNT211 Multiple solid tumors BNT3214 Multiple solid tumors Pumitamig1 Multiple solid tumors8 Pumitamig1 + Beruzatatug pelitecan5 Adv. NSCLC BNT1167 1L adv. NSCLC Pumitamig1 2L+ EGFRm NSCLC8 Pumitamig1 1L met. CRC Gotistobart4 2L+ sqNSCLC Trastuzumab pamirtecan3 Met. BC BNT314/GEN10596 Multiple solid tumors Elfetabart Drozuntecan3 Multiple solid tumors Pumitamig1 1L adv./met. TNBC8 Pumitamig1 + Trastuzumab pamirtecan3 Adv./met. BC9 Beruzatatug pelitecan5 Multiple solid tumors8 Pumitamig1 2L Glioblastoma8 Pumitamig1 1L met. Gastric Pumitamig1 1L ES-SCLC Trastuzumab pamirtecan3 2L EC Beruzatatug pelitecan5 Multiple solid tumors Sacituzumab drozuntecan3 Multiple solid tumors Pumitamig1 + BNT314/GEN10596 Met. CRC9 Trastuzumab pamirtecan3 Multiple solid tumors Beruzatatug pelitecan5 Adv./met. BC8 Pumitamig1 2L NEN8 Pumitamig1 1L NSCLC Pumitamig1 1L adv. NSCLC BNT329 Multiple solid tumors Pumitamig1 + BNT3212 Multiple solid tumors Gotistobart4 PROC Pumitamig1 2L adv./met. NSCLC Pumitamig1 Unresectable Stage III NSCLC Gotistobart4 Met. CRPC Pumitamig1 + BNT3213 1L HCC8,9 Pumitamig1 1L met. CRC8 Pumitamig1 1L met. PDAC Pumitamig1 2L SCLC8 Gotistobart4 Multiple solid tumors Pumitamig1 + Elfetabart Drozuntecan3 Adv./met. NSCLC and SCLC9 Pumitamig1 1L ES-SCLC8 Pumitamig1 1L/2L adv./met. TNBC Pumitamig1 1L adv./met. TNBC10 Pumitamig1 1L adv. HCC Pumitamig1 + Sacituzumab drozuntecan3 Multiple solid tumors9 Pumitamig1 1L/2L+ ES-SCLC Pumitamig1 or Sacituzumab drozuntecan + Elfetabart Drozuntecan3 Multiple solid tumors9 mRNA Immunotherapy Next Generation Immunomodulator Targeted Therapy Novel-novel Combination
26 Partnered with: 1. University of Pennsylvania; 2. Pfizer; 3. Fosun Pharma; 4. Funded by the Gates Foundation; 5. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI). mRNAAntibody BioNTech’s Infectious Diseases Pipeline Phase 1 Phase 1/2 Phase 2 Commercial BNT1631 HSV BNT1644 Tuberculosis BNT1665 Mpox BNT1622,3 COVID-19 BNT351 HIV BNT1684 HIV
Abbreviation Directory 27 n L nth line FY Fiscal year OS Overall survival AACR American Association for Cancer Research G7 markets Canada, France, Germany, Italy, Japan, GB, USA PDAC Pancreatic ductal adenocarcinoma ADC Antibody-drug conjugate GB Great Britain PD-(L)1 Programmed cell death protein (ligand) 1 adj. Adjuvant HCC Hepatocellular carcinoma (m) PFS (Median) Progression-free survival adv. Advanced HER2 (or 3) Human epidermal growth factor receptor 2 (or 3) PoC Proof of concept B7-H3 Also known as CD276, cluster of HIV Human immunodeficiency virus PROC Platinum-resistant ovarian cancer differentiation 276 HNSCC Head and neck squamous cell carcinoma R&D Research and development BC Breast cancer HPV 16 Human papilloma virus 16 RCC Renal cell carcinoma BLA Biologics License Applications HR Hormone receptor (ES)SCLC (Extensive stage) Small cell lung cancer BMS Bristol Myers Squibb HSV Herpes simplex virus SEC Securities and Exchange Commission CEPI Coalition for Epidemic Preparedness IA Interim Analysis SG&A Selling, general and administrative expenses Innovations IFRS International financial reporting standards SITC Society of Immunotherapy of Cancer CPS Combined positive score IIT Investigator initiated trial SoC Standard of Care CRC Colorectal cancer iNeST Individualized NeoAntigen-Specific Therapy (n)Sq (non-)Squamous (m)CRPC (met.) Castration resistant prostate cancer IO Immuno-oncology TCE T cell engager CRT Chemoradiation therapy M&A Merger and acquisition TM Trademark CTLA-4 Cytotoxic T-Lymphocyte-Associated Protein 4 met. Metastatic TME Tumor microenvironment DCR Disease control rate Mpox Monkey pox TNBC Triple-negative breast cancer DLL3 Delta-like ligand 3 mRNA Messenger ribonucleic acid Treg Regulatory T DoR Duration of response MSS Microsatellite stability TROP2 Trophoblast cell surface antigen 2 EC Endometrial cancer NEN Neuroendocrine neoplasm VEGF-A Vascular endothelial growth factor A EGFR(m) (mutated) Epidermal growth factor receptor (sq) NSCLC (squamous) Non-small cell lung cancer WCLC World Conference of Lung Cancer ESMO European Society for Medical Oncology (c)ORR (confirmed) Objective response rate FixVac Fixed Antigen Vaccine (u)ORR (unconfirmed) Objective response rate